An extension of the single threshold design for monitoring efficacy and safety in phase II clinical trials.
Brutti, P
An extension of the single threshold design for monitoring efficacy and safety in phase II clinical trials. [electronic resource] - Statistics in medicine Jun 2011 - 1648-64 p. digital
Publication Type: Journal Article
1097-0258
10.1002/sim.4229 doi
Algorithms
Antineoplastic Agents--adverse effects
Bayes Theorem
Bias
Child
Clinical Trials, Phase II as Topic--adverse effects
Computer Simulation
Drug-Related Side Effects and Adverse Reactions
Epidemiologic Research Design
Humans
Interleukin-12--adverse effects
Melanoma--drug therapy
Models, Statistical
Neuroblastoma--drug therapy
Probability
Safety--statistics & numerical data
Sample Size
Treatment Outcome
An extension of the single threshold design for monitoring efficacy and safety in phase II clinical trials. [electronic resource] - Statistics in medicine Jun 2011 - 1648-64 p. digital
Publication Type: Journal Article
1097-0258
10.1002/sim.4229 doi
Algorithms
Antineoplastic Agents--adverse effects
Bayes Theorem
Bias
Child
Clinical Trials, Phase II as Topic--adverse effects
Computer Simulation
Drug-Related Side Effects and Adverse Reactions
Epidemiologic Research Design
Humans
Interleukin-12--adverse effects
Melanoma--drug therapy
Models, Statistical
Neuroblastoma--drug therapy
Probability
Safety--statistics & numerical data
Sample Size
Treatment Outcome